The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
 
Kevin Kalinsky
Employment - ADC Therapeutics (I); EQRx (I)
Stock and Other Ownership Interests - ADC Therapeutics (I); EQRx (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; bioTheranostics; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Gilead Sciences; Lilly; Menarini Silicon Biosystems; Merck; mersana; Mersana; Novartis; Pfizer; ProteinQure; Puma Biotechnology; Regor; Relay Therapeutics
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Evandro de Azambuja
Honoraria - AstraZeneca; Boehringer Ingelheim; Gilead Sciences; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Gilead Sciences; Lilly; Menarini; MSD Oncology; Novartis; Roche/Genentech
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Belgian Society of Medical Oncology (BSMO); Breast International Group; ESMO
 
Sherene Loi
Honoraria - Adanate; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Sung-Bae Kim
Consulting or Advisory Role - AstraZeneca; BeiGene; BNT; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Genexine; Gilead Sciences; Lilly (Inst); Novartis; TiumBio
Travel, Accommodations, Expenses - Lilly
 
Clinton Yam
Stock and Other Ownership Interests - Cytodyn
Consulting or Advisory Role - Gilead Sciences
Research Funding - Amgen (Inst); BostonGene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Bernardo Rapoport
Consulting or Advisory Role - Acino Pharma South Africa; Astra-Zeneca South Africa; Janssen; MSD South Africa
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; SK Biopharmaceutical
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Barbara Pistilli
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Myriad Genetics; Novartis; Olema Oncology (Inst); PIERRE FABRE; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); DAIICHI-SANKYO (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Accord Healthcare; AstraZeneca; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Pfizer; Pierre Fabre
 
Wassim McHayleh
Stock and Other Ownership Interests - Relay Therapeutics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Natera; Stemline Therapeutics
Speakers' Bureau - Agendia; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Merck; Natera; Pfizer; Stemline Therapeutics
 
David Cescon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; GenomeRx; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); GenomeRx (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); PearBio (Inst); Pfizer (Inst); ProteinQure (Inst); RayzeBio (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
(OPTIONAL) Uncompensated Relationships - Inivata/NeoGenomics
 
Junichiro Watanabe
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin; Lilly Japan; MSD; Nipro Corporation; Pfizer
Consulting or Advisory Role - Daiichi-Sankyo; Gilead Sciences; Lilly
Research Funding - Bristol-Myers Squibb Japan (Inst); Daiichi-Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
 
Alejandro Lara
Consulting or Advisory Role - Ipsen; MSD Oncology
Speakers' Bureau - Bayer; MSD; MSD Oncology; Takeda
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; MSD Oncology; Roche; Roche
 
Ruffo Freitas-Junior
Honoraria - Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD; MSD/AstraZeneca; Novartis (Inst); zeiss
Consulting or Advisory Role - Gilead Sciences (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Libbs (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii Sankyo; Gilead Sciences; Libbs; MSD/AstraZeneca
 
Alain Lortholary
Honoraria - AstraZeneca; clovis oncology; MSD; Novartis; Roche; Tesaro/GSK; Tesaro/GSK
 
Kenneth Caldwell
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Yanan Huo
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Catherine Lai
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Genentech/Roche
 
Sara Tolaney
Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences